<DOC>
	<DOCNO>NCT02848833</DOCNO>
	<brief_summary>To monitor safety profile effectiveness Empagliflozin Korea patient type 2 diabetes mellitus routine clinical practice set</brief_summary>
	<brief_title>JARDIANCE Regulartory Post Marketing Surveillance Korean Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients start JARDIANCE® accordance approve label Korea 2 . Age = 19 year enrolment 3 . Patients sign data release consent form Exclusion criterion : 1 . Known hypersensitivity empagliflozin excipients 2 . Patients type 1 diabetes treatment diabetic ketoacidosis 3 . Patients persistent estimate Glomerular Filtration Rate &lt; 60 mL/min/1.73 m2 , end stage renal disease dialysis 4 . Patients rare hereditary condition galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 5 . Patients empagliflozin contraindicate accord local label JARDIANCE®</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>